We are pleased that the NT-501 treatment has a beneficial biological effect on the retina in these two clinical trials demonstrated and we are confident vision that is observed when all the information on the completion of the clinical trials, said Stephen Rose, chief research officer of the Foundation Fighting Blindness. We are very proud of our long-term support for NT-501 and the innovative technology of ECT revia . .

. We are confident that the biological changes observed in RP patients with NT-501-treated patients, an advantage in visual function cause, said Dr. ,, director of the retina Foundation of the Southwest, and principal investigator for the RP studies. But the progression of this disease slowly and we do not have visual benefit visual benefit in the treated eye relative to the control eye on this relatively short 12-month period , added Dr, added Dr.

naltrexone hydrochloride 50 mg

‘But let is still to find do not quantitative statement that these oils not to obtain or physiological effect for the people in general. ‘.

Other articles from category "diagnostics":

Random articles